Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 122 clinical trials
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

The purpose of this study is to determine the best management strategy to maintain remission in patients with ANCA vasculitis who have been treated with rituximab induced B cell depletion for at

  • 0 views
  • 23 Jan, 2021
A Randomized Multicenter Study for Isolated Skin Vasculitis

Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.

  • 176 views
  • 26 Apr, 2021
  • 14 locations
Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Rationale: Most recent insights in the treatment for patients with ANCA-associated vasculitis (AAV) have demonstrated that 'tailored' maintenance treatment with rituximab (RTX) is effective to

  • 0 views
  • 22 Jan, 2021
  • 1 location
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

ANCA vasculitis is a pauci-immune systemic small vessel vasculitis. The anti-neutrophilic cytoplasmic antibodies (ANCA) are pathogenic and cause disease by activating neutrophils which damage

cyclophosphamide
rituximab
prednisone
azathioprine
  • 0 views
  • 26 Jan, 2021
  • 1 location
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of a rare group of inflammatory diseases: ANCA associated vasculitis. Soluble CD95 Ligand might have a

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis. The purpose of this clinical trial is to determine

wegener's granulomatosis
ct angiography
angiography
anca
churg-strauss syndrome
  • 15 views
  • 28 Mar, 2021
  • 5 locations
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Autoantibodies (ANCA)-associated vasculitis) patients who have reached ESRD (end-stage renal disease). Our hypothesis is that discontinuation of immunosuppressive therapy in AAV patients with ESRD will not

glomerular filtration rate
nephropathy
renal injury
immunosuppression
immunosuppressants
  • 25 views
  • 14 Jun, 2021
  • 74 locations
Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)

The purpose of this study is to determine the efficacy and safety of a new drug, mycophenolate mofetil, for the treatment of relapses of ANCA-associated vasculitis (Wegener's

anca-associated vasculitides
vasculitis
anca
anca associated vasculitis
mycophenolate mofetil
  • 21 views
  • 07 Nov, 2020
  • 1 location
Biodistribution Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis Vasculitis or Pulmonary Sarcoidosis

arthritis, vasculitis or pulmonary sarcoidosis as well as radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and tolerability of the tracer in healthy volunteers.

vasculitis
pulmonary sarcoidosis
  • 0 views
  • 19 Jun, 2021
  • 1 location
Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease

Anti-neutrophil cytoplasmic antibodies (ANCA), directed against myeloperoxidase (MPO) and against proteinase 3 (PR3), have a pathogenic role during ANCA (AAV) vasculitis. Glomerular basement

coagulopathy
renal impairment
immunosuppressive agents
  • 0 views
  • 23 Jan, 2021
  • 1 location